Document is current
Any future updates will be listed below
-
Authors
Kim, Ryul
Yu, Jonghan https://orcid.org/0000-0001-9546-100X
Lim, Joonoh
Oh, Brian Baek-Lok https://orcid.org/0000-0001-6007-5176
Nam, Seok Jin
Kim, Seok Won
Lee, Jeong Eon
Chae, Byung Joo
Kim, Ji-Yeon https://orcid.org/0000-0002-4223-1929
Park, Ga Eun
Kang, Bong Joo
Paik, Pill Sun
Bae, Soo Yeon https://orcid.org/0000-0003-0551-7618
Yoon, Chang Ik
Lee, Young Joo https://orcid.org/0000-0001-5352-8093
Kim, Dooreh
Shin, Kabsoo https://orcid.org/0000-0002-6709-0894
Lee, Ji Eun
Kang, Jun https://orcid.org/0000-0002-7967-0917
Lee, Ahwon
Connolly-Strong, Erin
Lee, Sangmoon
Lee, Bo Rahm
Lee, Yuna https://orcid.org/0000-0003-3700-0824
Yi, Ki Jong
Kwon, Young Oh
Chun, In Hwan
Park, Junggil
Kim, Jihye
Choi, Chahyun
Shin, Jong Yeon
Lee, Hyungjung
Kim, Minji
Park, Hansol
Jeong, Ilecheon
Yi, Boram
Lee, Won-Chul https://orcid.org/0000-0001-8052-2420
Lee, Jeong Seok
Park, Woo Chan
Kim, Sung Hun
Choi, Yoon-La
Lee, Jeongmin https://orcid.org/0000-0002-4266-7984
Ju, Young Seok https://orcid.org/0000-0002-5514-4189
Park, Yeon Hee https://orcid.org/0000-0003-4156-9212
- License Information
-
More Information
Article History
Received: 15 September 2024
Accepted: 27 October 2025
First Online: 3 December 2025
Competing interests
: Y.S.J. and J.S.L. are co-founders of Inocras, a San Diego-based precision medicine company. Y.H.P. has received grants from MSD, AstraZeneca, Pfizer, Gencurix, Roche, Inocras and Novartis, and consulting fees from AstraZeneca, MSD, Pfizer, Eisai, Lilly, Roche, Gilead, Daiichi-Sankyo, Menarini, Everest and Novartis. R.K., J. Lim, B.B.-L.O., E.C.-S., S.L., B.R.L., Y.L., K.J.Y., Y.O.K., I.H.C., J.P., J. Kim, C.C., J.Y.S., H.L., M.K., H.P., I.J., B.Y. and W.-C.L. are employees of Inocras. The other authors declare no competing interests.
